Beyond Extraordinary

Giving Opportunities

Name	*Gift*
Atrium Promenade	***$5 million***
The Phlebotomy Treatment Center	*$5 million*
3-Level Parking Garage	*$5 million*
Auditorium	*$5 million*
Family Education Center	*$5 million*
Grand Concourse/Waiting Area	*$2 million*
Dining Room (48 seats)	*$2 million*
Diagnostic Laboratory Suite	*$2 million*
Administration Wing	*$1 million*
Resource Library	*$1 million*
Conference Suite (18 seats)	*$1 million*
Conference Wing (4 rooms)	*$1 million*
Retail Pharmacy	*$1 million*
Food Preparation Instruction Area	*$500,000*
Chairman's Office Suite	*$500,000*
Tranquility Room	*$500,000*

Atrium Promenade

Patients will be welcomed to the new John Theurer Cancer Center via the Atrium Promenade, an airy and inviting space offering easy access to all the services they need. Here they will confirm appointments, complete paperwork, and have tests and blood work done. Everything will be designed to ensure that patients know where to go and when, and how to get there.

First-time visitors will be introduced to all the resources and facilities within the center. The administrative staff is currently developing a system that will help guide the patient through the building. Like personal shoppers, 'patient navigators' will assess the unique needs of each person and pinpoint the services most likely to benefit him or her.

From this floor, administrators will manage all cancer center operations, including strategic planning, budget management, supervision of the nursing staff, and job training for employees. Through their ongoing negotiations with Medicare and other health insurance providers, they will also ensure that our patients receive extraordinary care at the best possible value.

Left to right

Andrew Pecora, M.D.
Chairman & Executive Administrative Director, the John Theurer Cancer Center

Elizabeth Koller, R.N.
Administrative Director, the John Theurer Cancer Center

André Goy, M.D., M.S.
Deputy Director, the John Theurer Cancer Center; Chief, Division of Lymphoma Oncology; and Director of Cancer Research

Dan Smith, M.D.
Chief, Division of Gynecologic Oncology and Vice Chairman, the John Theurer Cancer Center

Research and Clinical Trials

Great medical centers have great research programs, and HUMC is no exception. More than ever, we are putting the discoveries of our lab into the hands of our clinicians to improve outcomes for patients. We work jointly with the National Cancer Institute to develop innovative treatments for a variety of cancers, and our continuing research in stem cell transplantation and immunotherapy has helped to save many lives while earning us a worldwide reputation in this field.

Essential to our success is the dynamic intellectual exchange between scientists and medical oncologists–interaction that the new John Theurer Cancer Center will serve to enhance. By centralizing our operations, we will afford our research chief more opportunities to consult and share ideas with division chiefs and their staffs. Our research nurses and data coordinators–who collect and manage information for new pharmaceutical trials–will no longer be housed apart from their colleagues, but will work in close proximity with them as key members of each division's specialized team of experts.

This bench-to-bedside collaboration between lab and treatment teams should also help to increase patient participation in clinical trials. More than half our patients are eligible for the more than 75 trials we're now conducting. Of those patients, three-quarters are enrolled–a record that surpasses the performance of many of the finest hospitals. Our investment in research and clinical trials is the surest path to greater personalized care, cancer prevention, and cure.

Robert Korngold, Ph.D.
Chairman of the Department of Research
Hackensack University Medical Center

André Goy, M.D., M.S.
Deputy Director, the John Theurer Cancer Center; Chief, Division of Lymphoma Oncology; and Director of Cancer Research

Dr. Korngold leads the research division at HUMC, where scientists are investigating ways to improve prevention and treatment of disease. His specialty is adult blood and marrow stem cell transplantation.

Dr. Korngold has devoted his career to refining the stem cell transplantation process and studying the mechanisms of graft-versus-host disease, a potentially fatal side effect of stem cell transplantation that occurs when donor cells stage an immune response to organs in the patient's body and attack them.

"Research is the key to our future, and we're becoming a national leader in this area. I work with the clinicians on their own research goals, and the new cancer center will facilitate that interaction. There are many diseases we don't yet understand. We have a lot of potential treatments waiting in the wings. An immunotherapeutic approach can save lives, and that's what we're after."

Dr. Korngold

"Thanks to the progress of technology as well as the human genome sequencing, we can now characterize the tumors from the molecular standpoint. A tumor's behavior, its aggressiveness, sensitivity or resistance to chemotherapy, is dependent on the sum of the molecular defects accumulated within the tumor cells over time." Dr. Goy

Dr. Goy's research centers on developing biomarkers for both novel and conventional therapies in lymphoma as a model. As Deputy Director of the John Theurer Cancer Center, Dr. Goy is responsible for clinical and translational cancer research at HUMC, with the goal of integrating these biomarkers across all divisions of the cancer center to hopefully design more molecularly relevant clinical trials in the future.

Thea M. Friedman, Ph.D.
Director of Research Laboratory Services

K. Stephen Suh, Ph.D.
Laboratory Director
Tumor Bank and Genomics Program

Dr. Friedman directs basic research at the cancer center laboratory, where scientists are looking for ways to prevent or cure cancer by studying the mechanisms of the disease. She specializes in the field of blood and marrow stem cell transplantation.

Dr. Friedman's research has concentrated on reducing the incidence and severity of graft-versus-host disease, which occurs when some of the donated, disease-fighting T-cells recognize the patient's organs as foreign objects and attack them. Using a molecular finger printing technology, Dr. Friedman can distinguish those 'bad' T-cells from the 'good' ones, which attack the malignancy instead. Her goal is to enhance the ability of the 'good' cells to combat leukemia, myeloma, and other cancers. The research grants she has received in this field are among the most prestigious awarded by the National Institutes of Health.

"I always knew that basic research would be my calling, and the clinicians here are staunch supporters of our research. We help each other in whatever ways we can. They take time out of their incredibly overburdened schedules to engage in intellectual exchange with us."
Dr. Friedman

"For the past 15 years, scientists have spent billions of dollars in an unsuccessful search for a cancer biomarker, failing because some of their cancer samples were junk-quality. In our research, we use only the finest specimens. So I'm confident we'll achieve major breakthroughs in biomarker discovery at our new cancer center."
Dr. Suh

Dr. Suh's research at the Tumor Bank laboratory focuses on science to identify molecular markers (biomarkers) for multiple human cancers. Biomarker discovery projects are designed specifically for each cancer type, and the laboratory is currently working on lymphoma and ovarian cancer projects. The laboratory has set up the world's largest collection of cancer cell lines for mantle cell lymphoma and ovarian cancer to be used in research. The Tumor Bank program is also developing innovative methods for tissue procurement to collect cancer specimens with the highest quality.

Jonathan Walland, LL.B., M.B.A.
Director of Clinical Research

Richard Rosenbluth, M.D.
Chief, Division of Geriatric Oncology

Jonathan Walland leads the clinical research program at the cancer center, which offers patients access to over 75 experimental cancer therapies. Working with a multidisciplinary team of more than 50 research nurses, research data coordinators, and regulatory staff, he helps bring together research pharmaceutical companies and patients to provide early access to the most promising clinical trials with exciting new treatments.

"Cancer risk increases with age, and by 2030, a fifth of the population will be 65+. Elderly patients who are vulnerable and frail need special assessment and the multidisciplinary approach in which we specialize. The new center will better enable us to integrate services for them and focus on their unique needs." Dr. Rosenbluth

"I left the pharmaceutical industry because here I can be close to patients and see, first-hand, the life-saving impact of new therapies. Using clinical trials not as an adjunct to standard medicine, but as a fully integrated part of treatment, we interact with patients to understand their needs and provide access to cutting-edge medicine." Mr. Walland

Dr. Rosenbluth, a hematologist and oncologist, has been on the medical staff at HUMC for more than 30 years and is medical director of HUMC's hospice program. He was recently chosen to head the cancer center's new geriatric oncology program, one of the few in the world to offer the complete depth of personalized cancer care needed by senior patients.

Dr. Rosenbluth is also principal investigator for the cancer center's Clinical Community Oncology Program, through which physicians at HUMC collaborate with scientists all over the country on clinical trials supported by the National Cancer Institute.

Nursing Leadership

Left to right:

Joan Monaghan, M.S., R.N., A.P.N., C.P.
Coordinator of Psychosocial Support Services

Stacey McArdle, R.N., B.S.N., M.A.
Case Manager

Laura Kudlacik, R.N., B.S.N.
Nurse Manager

Laura Metcalfe, M.S.N., R.N., A.P.N., C, A.O.C.N.S.
Advanced Practice Nurse

Karen Nelson, R.N.
Nurse Manager

Thomas Capiaghi, R.N., B.S.N.
Case Manager

Both figuratively and literally, the nursing staff is the face of the cancer center. Above all others, theirs are the faces our patients look forward to seeing when they come here for therapy. For among all the dedicated caregivers at HUMC, nurses have the most intimate connection with the people we serve.

As any of our doctors will tell you, nurses play a vital role in our multidisciplinary approach to patient care. They are carefully trained to communicate with the patient, understand the challenges of the illness, observe symptoms, and document responses to treatment. As a result, they're superbly positioned to offer invaluable insights into the patient's condition, attitude, and emotional state–insights that inform the tailored treatment plan that a team of medical experts will devise.

Our nurses perform a wide range of other duties: administering blood transfusions and biologic therapies; educating patients about clinical trials; and managing and coordinating care. With all our nurses working together in the new cancer center, their teamwork and camaraderie will be further enhanced, ensuring the delivery of seamless care for every patient.

Wellness and Support Services

Headquartered on the Atrium Promenade, a comprehensive variety of support services that promote wellness and expand the definition of personal care will be readily accessible to all cancer center patients who need them.

The breadth of these ancillary services is proof of HUMC's commitment to a holistic approach to wellness–one informed by its affiliation with Planetree, a pioneering non-profit organization. Planetree's patient-centric model of care encourages healing in all dimensions: mental, emotional, spiritual, and social as well as physical.

Planetree places great emphasis on the importance of architectural and interior design in the healing process: hence the spacious, light-filled environment of the new John Theurer Cancer Center. Here, comfort and privacy will support the healing partnership between patients and care-givers. In life-enhancing surroundings, patients will receive information, education, and counseling–all with the restorative value of the human touch.

Existing services will be relocated to the new center and new services will be added. Patients will have the opportunity to receive help with pain relief and palliative care; improve their quality of life through rehabilitation therapy and psychological treatment; and learn more about regaining and maintaining their health through exercise, yoga, nutrition and cooking. They will be encouraged to visit our reading and research library, our prosthetic boutique, and our fully equipped day spa.

At the Pain Center, we will continue to combine leading-edge technology and treatment methods with holistic, personalized care to reduce the pain of cancer-related conditions.

In the hospital's holistic approach to wellness, its BEYOND Day Spa has proven to be a major asset and a perfect complement to its top-flight medical services. Patients coming to the new cancer center for diagnosis and treatment can enjoy the stress-reducing benefits of an afternoon manicure or massage. Here, and throughout the rest of the facility, they will discover the indivisible connection between being well and feeling good.

Green Building and Sustainable Design

A hospital's primary concern, of course, is for the health of its patients. But today no institution can build a large new structure without considering its impact on the environment and the health of the planet. HUMC's leadership in energy and environmental design, previously demonstrated by its recent construction of the LEED-certified Women & Children's Pavilion, will be extended to the building of the new cancer center. The new John Theurer Cancer Center will be designed to meet the requirements of 'green' construction and receive LEED-certification from the U.S. Green Building Council.

Green buildings are good both for the outside environment and the people inside them. Though more costly than conventional buildings, greening eliminates asthma and allergy triggering toxins and carcinogens from the air. For example, engineers are now using scraps of blue jeans as insulation material in place of fiberglass (which contains toxic formaldehyde) in many new structures. The U.S. Department of Energy strongly supports HUMC's green building efforts and regards the new cancer center as an innovative prototype for future hospital construction.



Our new building will be designed to protect the health of its occupants (patients, staff, and visitors), and also the health of the surrounding community and the larger global community. Made of sustainable and environmentally-friendly building materials, it will have a highly efficient ventilation system, a limited quantity of wasteful emissions, and a maximum of available daylight. Proper land use and transportation planning, landscape and water management on the grounds, and water conservation efforts within the building will keep the environmental impact of the John Theurer Cancer Center to a minimum, both locally and far beyond the immediate vicinity.

Hackensack University Medical Center Foundation

360 Essex Street, Suite 301, Hackensack, NJ 07601-8566
www.humcfoundation.com